- As GLP-1 medications increase in popularity, researchers continue to examine potential side effects.
- The FDA is investigating reports of side effects from GLP-1 receptor agonists, including suicidal ideation and hair loss.
- A large new study found no link between semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, and suicidal ideation.
GLP-1 drugs, such as semaglutide, liraglutide, and tirzepatide, are type 2 diabetes medications that have become popular over the last year for weight loss.
It’s estimated around 24 million people in the United States, or 7% of the population, will take GLP-1 medications by 2035.
Wegovy, Saxenda, and Zepbound are currently the GLP-1 medications that are FDA-approved as weight loss drugs. Ozempic, Mounjaro, and others may be prescribed off-label to help with weight loss.
As demand for these medications increases, researchers and health experts are looking closely at the potential side effects of GLP-1 receptor agonists.
The Food and Drug Administration (FDA) is investigating
But
Still, previous research has shown that potential side effects of GLP-1 medications include
Despite the possible side effects, GLP-1 drugs are considered safe. Medical News Today spoke with three obesity experts to learn more.
The FDA investigation is not the first time an association between suicidal ideation and GLP-1 medications has been reviewed.
The European Medicines Agency (EMA) began investigating this potential side effect in July 2023.
However, a
Read the full article here